Resources

o2h discovery is excited to announce Ubiquigent as a winner of the o2h Kickstarter Competition. Ubiquigent Limited (Ubiquigent), a revenue- and IP-generating drug discovery company dedicated to enabling deubiquitinase (DUB)-focused drug discovery.

RoslinCT has entered into a strategic partnership with Gamida Cell Ltd. to manufacture their FDA-Approved Cell Therapy Omisirge.®

The UKHSA Conference 2025, delivered in partnership with the FPH, will explore the full breadth of UKHSA’s work; from science-driven research to effective policy implementation.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.

A new network will foster collaboration among regulators, industry, and researchers to ensure there is a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these innovative treatments.

Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK.

The Milner Therapeutics Institute are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance breakthrough scientific research and technologies.

£20 million Series A financing underway to support development of lead product

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.

Excelra has partnered with Orogen Therapeutics, an innovative DNA-Encoded Library (DEL) and AI-driven biotechnology company currently developing a portfolio of best-in-class small molecule treatments.

Innovating manufacturing processes is key to revolutionising access to advanced cell and gene therapies - this blog explores how Tolemy Bio's co-founders, Caelan and Alex, are leveraging cutting-edge technologies like AI, biochemical modelling, and omics data to overcome complex challenges and drive global scalability.

BIA today announces Blood Cancer UK as its charity partner of the year for 2025. This partnership demonstrates BIA’s commitment to driving meaningful change through collaboration.

Poolbeg Pharma announces key insights from its poster presentation at the 66th American Society of Hematology ('ASH') Annual Meeting and Exposition, San Diego, California.

Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation committed to the advancement of cell and gene therapies has released its Good Manufacturing Practice (GMP) Report 2024.

Degree apprentice with AstraZeneca, Emily Butterworth, becomes the first Manchester Met apprentice to be highly commended in the Royal Society of Biology’s Apprentice of the Year Awards 2024.

Facility dedicated to cryopreservation of leukapheresis starting materials to support clinical and commercial cell-based therapy programs